RT Journal Article
T1 RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
A1 Zhou, Nan
A1 Gutiérrez Uzquiza, Álvaro
A1 Zheng, Xiang Yu
A1 Chang, Renxu
A1 Vogl, Dan T.
A1 Garfall, Alfred L.
A1 Bernabei, Luca
A1 Saraf, Anita
A1 Florens, Laurence
A1 Washburn, Michael P
A1 Illendula, Anuradha
A1 Bushweller, John H.
A1 Busino, Luca
AB Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)- dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Using an unbiased screen based on mass spectrometry, we identified the Runt-related transcription factor 1 and 3 (RUNX1 and RUNX3) as interactors of IKZF1 and IKZF3. Interaction with RUNX1 and RUNX3 inhibits CRBN-dependent binding, ubiquitylation, and degradation of IKZF1 and IKZF3 upon lenalidomide treatment. Inhibition of RUNXs, via genetic ablation or a small molecule (AI-10-104), results in sensitization of myeloma cell lines and primary tumors to lenalidomide. Thus, RUNX inhibition represents a valuable therapeutic opportunity to potentiate IMiDs therapy for the treatment of multiple myeloma
PB Springer-Nature
SN 0887-6924
SN 1476-5551
YR 2019
FD 2019-02-13
LK https://hdl.handle.net/20.500.14352/115292
UL https://hdl.handle.net/20.500.14352/115292
LA eng
NO Ibáñez-Escribano A, Reviriego F, Vela N, Fonseca-Berzal C, Nogal-Ruiz JJ, Arán VJ, et al. Promising hit compounds against resistant trichomoniasis: Synthesis and antiparasitic activity of 3-(Ω-aminoalkoxy)-1-benzyl-5-nitroindazoles. Bioorganic & Medicinal Chemistry Letters [Internet]. abril de 2021 [citado 21 de enero de 2025];37:127843. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0960894X2100069X
NO National Cancer Institute
DS Docta Complutense
RD 1 may 2025